Abstract
Atherosclerotic cardiovascular disease is the leading cause of death in U.S. Macrophages are major cells responsible for atherosclerotic lesion development. (−)‐Epigallocatechin gallate (EGCG) abundant in green tea is valuable for the prevention and treatment of atherosclerosis. But low levels of stability and bioavailability limit its application in human. We encapsulated EGCG into biocompatible and biodegradable nanocarriers to increase its stability and cellular bioavailability. The stability of nanoencapsulated EGCG and native EGCG was measured at pH 7.2 at 4 °C and 25 °C. Nanoencapsulated EGCG was separated from nonencapsulated EGCG using a Sephadex™ G‐25 column. Total and nanoencapsulated EGCG was measured using a high‐performance liquid chromatography (HPLC) system. EGCG uptake by THP‐1 derived macrophages was measured using the same HPLC system. Nanoencapsulation significantly increased EGCG stability and its uptake by macrophages compared to native EGCG. This innovation portends a potential breakthrough in the prevention and treatment of atherosclerosis by using natural compounds with minimized immunogenicity and side‐effects.Grant Funding Source : NIH 1R15AT007013‐01
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
